The Translational Neurosciences research department has national and global industry partnerships from multiple cancer centers. These collaborations have resulted in promising new cancer therapies to extend the lives of patients with brain cancer and bridge the gap in neurotherapeutic discovery and development.

Drug Discovery and Nanomedicne (DDNM) research program peers


Institute for Systems Biology

  • Computational modeling and network pharmacology 

Icahn School of Medicine at Mount-Sinai

  • Plexin-B2 Function in Glioma Invasion and Glioma Stem Cell Maintenance (Roland Friedel)

The University of Texas Southwestern Medical Center

  • The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma


Past Clinical Research Industry Partners

  • Abbvie
  • Acadia
  • Adnexus Therapeutics, Inc.
  • Ambrx, Inc.
  • Amgen
  • Angiochem
  • Ariad Pharmaceuticals
  • Astra Zeneca
  • Cala Health
  • Celldex
  • Cellworks
  • EMD-Serono
  • EpicentRx
  • eTherapeutics
  • Genelux
  • Geron
  • GlaxoSmithKline, Inc.
  • ImmunoCellular
  • Inspyr
  • Kadmon
  • Medicenna
  • Merck
  • Neurobiological Technologies, Inc.
  • Northwest Biotherapeutics
  • Novartis Pharmaceuticals
  • Pfizer
  • SanBio
  • Schering-Plough
  • Sigma Tau
  • Sunovion
  • Tocagen
  • Triphase
  • UCB Pharma